Patrick Y Muller
Overview
Explore the profile of Patrick Y Muller including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
955
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hundhausen C, Frank J, Rimbach G, Stoecklin E, Muller P, Barella L
Cancer Genomics Proteomics
. 2019 Aug;
3(3-4):183-190.
PMID: 31394696
Vitamin E has been described in the literature as a regulator of gene expression. The gene-regulatory activity of vitamin E with regard to genes encoding cytochrome P450 (CYP) enzymes, which...
2.
Uteng M, Urban L, Brees D, Muller P, Kullak-Ublick G, Bouchard P, et al.
Drug Discov Today
. 2018 Sep;
24(1):285-292.
PMID: 30244081
With increasing expectations to provide evidence of drug efficacy, safety, and cost-effectiveness, best-in-class drugs are a major value driver for the pharmaceutical industry. Superior safety is a key differentiation criterion...
3.
Secondary pharmacology: screening and interpretation of off-target activities - focus on translation
Whitebread S, Dumotier B, Armstrong D, Fekete A, Chen S, Hartmann A, et al.
Drug Discov Today
. 2016 May;
21(8):1232-42.
PMID: 27140035
Secondary pharmacology is an essential component of drug discovery and is used extensively in the pharmaceutical industry for achieving optimal specificity of new drugs via early hazard identification and off-target...
4.
Muller P, Dambach D, Gemzik B, Hartmann A, Ratcliffe S, Trendelenburg C, et al.
Drug Discov Today
. 2015 May;
20(9):1135-42.
PMID: 26022402
Treatment-related suicidal ideation and behavior (SIB) adverse events are under increasing public, legal and regulatory scrutiny. Prospective assessment of SIB is emerging as a challenging safety requirement by health authorities...
5.
Muller P, Milton M
Nat Rev Drug Discov
. 2012 Sep;
11(10):751-61.
PMID: 22935759
A key part of drug discovery and development is the characterization and optimization of the safety and efficacy of drug candidates to identify those that have an appropriately balanced safety-efficacy...
6.
Muller P
Adv Drug Deliv Rev
. 2010 Nov;
63(7):511-7.
PMID: 21034787
Exploratory clinical trials provide a strategy for rapid human entry of investigational drugs. Such clinical studies are typically conducted during early clinical development in phase I as first-in-human studies, have...
7.
Brennan F, Morton L, Spindeldreher S, Kiessling A, Allenspach R, Hey A, et al.
MAbs
. 2010 Apr;
2(3):233-55.
PMID: 20421713
Most therapeutic monoclonal antibodies (mAbs) licensed for human use or in clinical development are indicated for treatment of patients with cancer and inflammatory/autoimmune disease and as such, are designed to...
8.
Muller P, Milton M, Lloyd P, Sims J, Brennan F
Curr Opin Biotechnol
. 2009 Nov;
20(6):722-9.
PMID: 19896825
Dose selection for first-in-human (FIH) clinical trials with monoclonal antibodies (mAbs) is based on specifically designed preclinical pharmacology and toxicology studies, mechanistic ex vivo/in vitro investigations with human and animal...
9.
Muller P, Dieterle F
Expert Opin Drug Metab Toxicol
. 2009 Jul;
5(9):1023-38.
PMID: 19611406
Limited sensitivity and limited target organ specificity are the major drawbacks for most peripheral clinical pathology parameters traditionally used for monitoring organ integrity both during preclinical toxicological assessment and clinical...
10.
Muller P, Netscher T, Frank J, Stoecklin E, Rimbach G, Barella L
J Plant Physiol
. 2005 Jul;
162(7):811-7.
PMID: 16008109
Pharmacologically active compounds (e.g. from the groups of pharmaceutical drugs, cofactors or vitamins) often consist of two or more stereoisomers (enantiomers or diastereoisomers) which may differ in their pharmacodynamic/kinetic, toxicological...